HCM symptoms can vary in severity. Learn which ones warrant a call to the doctor and which are emergencies.

Participants will each receive a single intravenous infusion of AFTX-201 at doses determined from preclinical studies.

Learn about surgical options for hypertrophic cardiomyopathy (HCM), including septal myectomy, septal ablation, and heart ...

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

Cardiomyopathy is a disease of the heart muscles which may cause them to become enlarged and inflamed. Inflamed muscles become stretched, weak, less efficient at pumping blood and less able to ...

The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from ...

Please provide your email address to receive an email when new articles are posted on . Genetic risk for dilated cardiomyopathy was tied to elevated risk for secondary cardiomyopathies related to ...

The number of patients diagnosed with cardiomyopathy has increased substantially over the past two decades. This is the ...

The UPBEAT (c) clinical trial is a multicenter, open-label Phase 1/2 clinical trial designed to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of AFTX-201 in adults with ...

FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial in hereditary transthyretin amyloidosis with polyneuropathy. The decision allows the late stage study of Intellia's ...

Background A 56-year-old man with normal cardiac function received treatment with interferon α-2b for malignant melanoma. Eight months after the initiation of therapy he developed fatigue and dyspnea ...